Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
20 02 2021
20 02 2021
Historique:
pubmed:
8
10
2020
medline:
16
9
2021
entrez:
7
10
2020
Statut:
ppublish
Résumé
Randomized trials established the superiority of ibrutinib-based therapy over chemoimmunotherapy in chronic lymphocytic leukemia. Durability of progression-free survival (PFS) with ibrutinib can vary by patient subgroup. Clinical tools for prognostication and risk-stratification are needed. Patients treated with ibrutinib in phase II and III trials provided the discovery data set and were subdivided into discovery and internal validation cohorts. An external validation cohort included 84 patients enrolled in our investigator-initiated phase II trial. Univariable analysis of 18 pretreatment parameters was performed using PFS and overall survival (OS) end-points. Multivariable analysis and machine-learning algorithms identified four factors for a prognostic model that was validated in internal and external cohorts. Factors independently associated with inferior PFS and OS were as follows: Patients at increased risk of ibrutinib failure can be identified at treatment initiation and considered for clinical trials.
Identifiants
pubmed: 33026937
doi: 10.1200/JCO.20.00979
pmc: PMC8189626
doi:
Substances chimiques
Piperidines
0
ibrutinib
1X70OSD4VX
Adenine
JAC85A2161
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
576-585Commentaires et corrections
Type : CommentIn
Références
Nature. 2012 Sep 13;489(7415):309-12
pubmed: 22885698
Nat Med. 2013 Feb;19(2):202-8
pubmed: 23291630
Blood. 2018 Apr 26;131(17):1910-1919
pubmed: 29437592
Lancet Oncol. 2019 Jan;20(1):43-56
pubmed: 30522969
Blood. 2019 Mar 14;133(11):1205-1216
pubmed: 30602617
Cancer. 2015 Oct 15;121(20):3612-21
pubmed: 26193999
N Engl J Med. 2013 Jul 4;369(1):32-42
pubmed: 23782158
Ann Oncol. 2017 May 1;28(5):1050-1056
pubmed: 28453705
J Clin Oncol. 2017 May 1;35(13):1437-1443
pubmed: 28418267
Lancet Oncol. 2015 Feb;16(2):169-76
pubmed: 25555420
Lancet Haematol. 2019 Jul;6(7):e366-e374
pubmed: 31109827
Blood. 2019 Jul 11;134(2):111-122
pubmed: 31023700
Oncotarget. 2017 Mar 14;8(11):17936-17944
pubmed: 28212557
Blood. 2018 Aug 30;132(9):892-902
pubmed: 29997221
J Exp Med. 2018 Feb 5;215(2):681-697
pubmed: 29301866
Lancet Oncol. 2016 Jun;17(6):779-790
pubmed: 27185642
Blood. 2018 May 24;131(21):2357-2366
pubmed: 29483101
Blood. 2011 Jan 13;117(2):563-74
pubmed: 20940416
N Engl J Med. 2018 Dec 27;379(26):2517-2528
pubmed: 30501481
Blood. 2017 Mar 16;129(11):1469-1479
pubmed: 28049639
Nat Commun. 2016 May 20;7:11589
pubmed: 27199251
Nat Commun. 2017 Dec 19;8(1):2185
pubmed: 29259203
Lancet. 2020 Apr 18;395(10232):1278-1291
pubmed: 32305093
N Engl J Med. 2015 Dec 17;373(25):2425-37
pubmed: 26639149
J Clin Oncol. 2017 Sep 10;35(26):3010-3020
pubmed: 28715249
J Clin Oncol. 2013 Jan 1;31(1):88-94
pubmed: 23045577
N Engl J Med. 2019 Aug 1;381(5):432-443
pubmed: 31365801
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Lancet Oncol. 2018 Jan;19(1):65-75
pubmed: 29246803
N Engl J Med. 2014 Jun 12;370(24):2352-4
pubmed: 24869597
N Engl J Med. 2014 Jul 17;371(3):213-23
pubmed: 24881631
J Clin Oncol. 2018 Jul 1;36(19):1973-1980
pubmed: 29715056
N Engl J Med. 2019 Jun 06;380(23):2225-2236
pubmed: 31166681
Lancet Oncol. 2016 Oct;17(10):1409-1418
pubmed: 27637985
JAMA Oncol. 2015 Apr;1(1):80-7
pubmed: 26182309
Stat Med. 1997 Feb 28;16(4):385-95
pubmed: 9044528
N Engl J Med. 2014 Jun 12;370(24):2286-94
pubmed: 24869598